Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Darunavir and Ritonavir PK in Healthy Japanese Males
NCT01810887Phase 4Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- May 2008
- Primary completion
- Jul 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of darunavir in human immunodeficiency virus type 1 infection (HIV-1), sponsored by Janssen Pharmaceutical. Primary endpoints: Plasma Darunavir Concentration at 72 hours and Maximum Plasma Concentration of Darunavir at 72 hours. Started May 2008; status: completed.
02
Drugs
darunavir
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT01810887.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01810887.